AHOD1331: Cost Effectivess Analysis (CEA) of Brentuximab Vedotin in Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

HUMAN CLINICAL TRIAL - CONFIDENTIAL COG Protocol AHOD1331 entitled, “A Randomized Phase III Study of Brentuximab vedotin (IND#117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents” SUBCONTRACTE shall carry out the clinical trial research sub-study, “Cost Effectiveness Analysis (CEA) of Brentuximab Vedotin in Newly Diagnosed High-Risk Classical Hodgkin lymphoma (cHL) in Children and Adolescents,” set forth in the research protocol COG Protocol AHOD1331 entitled, “A Randomized Phase III Study of Brentuximab vedotin (IND#117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents”